A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Protocol: 
AAAQ9650
Phase: 
III

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

The purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment with interferon alfa-2b. This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse than treatment with interferon alfa-2b. In this study, you will get either MK-3475 or interferon alfa-2b. There will be about 1,378 people taking part in this study.

Are you Eligible? (Inclusion Criteria)

-Patients must have completely resected melanoma of cutaneous origin or of
unknown primary in order to be eligible for this study.
-Patients must be classified as Stage IIIA (N2a), IIIB, IIIC, or Stage IV
melanoma.
-Patients with melanoma of mucosal or other non-cutaneous origin are
eligible.

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States